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The p53 protein is a powerful tumor suppressor, often 
termed as ‘guardian of the genome’, whose function is lost 
in many types of human cancers (1). The loss of function 
is impelled either by de-regulation of the E3 ubiquitin 
ligase, MDM2 protein (2) or by the TP53 gene mutations of 
missense type (3). Mutations in TP53 gene occur at a very 
high frequency and range from 10% to 97% depending on 
the cancer type (4). Single amino acid substitutions result 
in the loss of tumor suppression transcription function, 
promote the change of the conformation and loss of the 
sequence-specific DNA binding function of mutant p53 
(mtp53) (5). 
The mutations in the TP53 gene not only terminate 
the wild-type activity of p53, but also foster gaining of 
new functions (GOFs) by p53 mutants. In healthy tissue, 
p53 regulates several hundreds of genes that are pivotal in 
sufficient functioning of the DNA repair pathway, apoptosis, 
cell cycle arrest and maintaining cell homeostasis. GOFs 
by mtp53 evolve to enable sustained growth of cancer cells 
through enhancing nutrient uptake, synthesis of building 
blocks or fueling the pool of NAD(P)+ that are essential 
for cancer cells to divide, migrate and become resistant to 
treatment. Therefore, p53 mutations are invariably linked 
with worse prognosis and shorter overall survival of cancer 
patients. 
Until recently, it was believed that mtp53 protein 
accumulates only in cancerous tissue (6). This was however 
put into question, as elevated levels of R172H mtp53 
were found in proliferating cells of normal tissues of adult 
p53R172H/R172H knock-in mice, with no sign of tumor 
transformation and at the levels similar to wild-type 
p53 (7). It is known that wild-type p53 accumulates upon 
activation by ionizing radiation (8) but mtp53 accumulated 
more rapidly in the mouse knock-in model and remained 
at elevated levels longer than wild-type p53. This implies 
that similar mechanisms govern the turnover of wild-type 
and mutant p53 proteins, however, mtp53 accumulation 
is restricted to proliferating cells only. Albeit, around 
2,000 mutations in the TP53 gene were described as well 
as the various mtp53-GOFs phenotypes, we are still on the 
way to divulge the mechanism underlying the emergence of 
certain mtp53 GOFs. Several studies ascribed these GOFs 
to the interactions of mtp53 with other transcription factors 
including NF-Y, SREBF2, ETS2 or ΔNp63. In addition, 
mtp53 binds to and inhibits other p53 family members like, 
TAp63 and TAp73 or wild-type p53 and interferes with 
miRNA biogenesis (9). 
The structural and functional diversity between different 
p53 mutants brings about high variance in the mechanisms 
how p53 mutants utilize their pro-oncogenic signatures 
and in result, making it very challenging to apply mtp53 
as a predictive factor for the treatment outcome in cancer 
therapies. Even though on-going efforts, it still remains of 
the outmost importance to determine the outcome of the 
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mtp53 gain of new functions across different tumor types. 
In August issue of Nature Cell Biology, Walerych 
et al. (10) addressed this challenge and singled out 
a universal mtp53 GOFs program that is an explicit 
transcriptional signature executing the expression of the 
proteasome machinery genes. 
To seek for the major common target of cancer-related 
p53 variants, Walerych et al. (10,11) utilized a multi-
omics approach converging on the whole-cell proteome 
and chip-sequencing analyses done in triple negative 
breast cancer (TNBC) cell line, MDA-MB-231 before 
and after silencing of mtp53. The analyses depicted a 72-
gene integrated signature, which after pathway analysis, 
identified the proteasome-ubiquitination pathway to be the 
most changed upon mtp53 depletion. Next, comparison 
of MDA-MB-231 transcriptome with mtp53 mRNA 
profiles in four other TNBC cell lines harbouring cancer-
related p53 mutants, revealed a signature of 205 common 
genes that in accordance with previous analysis, was most 
significantly enriched with genes coding for components of 
26S proteasome. To validate these findings in more clinical 
setting, the authors performed a patient-based analysis in 
which they found that proteasome gene signature associated 
with poor prognosis and with the mtp53 status in breast 
cancer patients. Consequently, mtp53 was attributed with 
the enhanced proteasomal activity as measured in cancer 
cell lines of various origins and in studies in R172H knock-
in mice. 
The transcriptional regulation of 37 genes coding 26S 
proteasome and immunoproteasome subunits, found 
among the 72- and 205-gene group, was attributed to the 
interaction of p53 mutants with Nrf2 [NF-E2-related factor 
2 (NFE2L2)], a pleiotropic transcription factor that regulates 
several different antioxidant pathways (12). Nrf2 is known 
to support the synthesis and regeneration of glutathione 
(GSH) and the production of NADPH. It is upregulated 
in cancers in consequence to loss of function mutations in 
Keap-1 and high levels of Nrf2 are associated with cisplatin 
resistance (13). Next, Nrf2 was shown to be upregulated by 
mtp53 and the mechanism is possibly via the cross-talk with 
Sp1 transcription that binds to NFE2L2 gene promoter (14).
The thorough analysis by Walerych and coworkers, 
demonstrates that Nrf2 engages mtp53s to the proteasomes’ 
genes, conversely to wtp53. Fluorescence microscopy 
analysis further corroborated the idea that mtp53s co-
opt with Nrf2 to drive the expression of proteasome 
genes, as mtp53 co-localizes with Nrf2 in the nucleus 
and interacts with Nrf2 in the nuclear fraction. Next, the 
affinity of Nrf2 to GOFs mtp53 protein was supported in 
immunoprecipitation studies after treatment of cells with 
PRIMA-1MET/APR-246, a molecule that was shown to 
restore wild-type conformation to mtp53 and to induce 
p53-related apoptosis (15). Only mutant and not APR-246 
activated wild-type p53 binds Nrf2. Hence, silencing of Nrf2 
and mtp53 reduces the mRNA levels of the 26S proteasome 
genes. Interestingly, mtp53 has opposing effect on other 
Nrf2 target gene HMOX-1 encoding heme-oxygenase 
(HO-1) (16), an enzyme involved in maintaining iron 
pool and free radicals clearance. This implies at least dual 
function of Nrf2-mtp53 axis in cancer cells. One would 
be attributed to regulating the expression of proteasome 
genes and the second to regulating the classical, Nrf2 anti-
oxidant response, though with the opposing outcome. Thus, 
although the up-regulation of proteasomal function has a 
clear survival advantage in cancer cells, downregulation of 
HO-1 still remains an unresolved puzzle. It is likely that 
other factors co-opt with Nrf2 and mtp53, to regulate the 
expression of HMXO-1 in mtp53 cancer cells or that the 
cellular effect that HO-1 exerts has already been taken over 
by other enzyme/pathway. Finally, it cannot be excluded 
that to study how Nrf2 regulates the expression of HMXO-
1 in mtp53 cancer cells, more hostile conditions, mimicking 
tumor environment need to be applied.
Ubiquitin-proteasome system (UPS) is the major 
mechanism by which the proteins are degraded and as such 
is a pivotal player in protein homeostasis (proteostasis). 
High incidence of gene mutations and aneuploidy in 
cancers lead to accumulation of mutated proteins that 
often fail in proper folding. Multiple evidence implies that 
cancer cells are dependent on UPS for the timely removal 
of accumulated, unfolded or aggregated proteins in order to 
escape the so-called ‘proteotoxic crisis’ and this has already 
been utilized in cancer treatment. Thus, the discovery of the 
proteasome inhibitor bortezomib provided the first direct 
evidence that it is possible to inhibit the UPS and is now 
exploited in the therapy for multiple myeloma (17). The 
efficiency of proteasomal inhibitors in certain tumor types is 
however, questionable. Hence, as mtp53s co-opt with Nrf2 
to up-regulate UPS, Walerych et al. further demonstrated, 
that mtp53-harbouring breast cancer cells are resistant 
to carfilzomib, novel proteasomal inhibitor and that the 
effect was dependent on mtp53. The resistance was due to 
the activation of the so-called ‘bounce-back’ effect where 
mtp53 up-regulates 26S proteasome genes transcription 
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after treatment with carfilzomib (Figure 1). The finding 
that Nrf2 co-immunoprecipitated with mtp53s but not with 
wild-type p53 protein, prompted authors to investigate if 
inhibition of GOFs mtp53 could overcome the resistance to 
carfilzomib. Thus, they showed that APR-246, a compound 
currently in phase I/II clinical trials, abolishes the resistance 
of TNBC cells to carfilzomib in mouse xenograft model. 
This constitutes promising grounds for further investigation 
of APR-246 in combination with proteasomal inhibitor in a 
more clinical setting.
26S proteasome is composed of 20S catalytic subunit 
that at its end is capped with 19S regulatory particles 
(Figure 1). The degradation by 26S proteasome is mediated 
by the ubiquitin system and p53 is one of its best-studied 
substrate. However, ubiquitin-independent degradation by 
20S proteasome has also been demonstrated to regulate p53 
and other tumor suppressors turnover and was found de-
regulated in cancers.
Figure 1 Cross-talk between mtp53 and Nrf2 in cancer. In normal cells p53 and other tumor suppressors like p73 undergo rapid turnover 
by ubiquitin-dependent and independent proteolysis. This is mediated by MDM2, E3 ubiquitin ligase to p53 and other E3 ligases (indicated 
as empty circles next to MDM2). During cancer development cells accumulate genomic instability that leads to oxidative and genotoxic 
stress which activates unfolded proteins response. Cancer cells in order to escape cell death, engage mtp53 to co-opt with Nrf2 transcription 
factor to upregulate the expression of 26S proteasome proteins. This enables rapid turnover of partially misfolded proteins and degradation 
of tumor suppressors. Next, upregulated 26S proteasomal pathway leads to resistance to proteasomal inhibitor carfilzomib. The interplay 
between mtp53-Nrf2 is additionally linked by a positive feedback loop. Here mtp53 interacts with Sp1 to enhance expression of Nrf2 factor 
and Nrf2 further stabilizes mtp53 by upregulating NQO1 that binds mtp53 and protects it from ubiquitin-independent degradation. The 
loop can be broken, hence enabling sensitivity to carilzomib by combining it with mutant p53 reactivating drug, APR-246.
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Nrf2 target, NAD(P)H:quinone oxidoreductase (NQO1), 
is an enzyme that reduces various quinones and is inhibited 
by the anticoagulant dicoumarol. NQO1 binds to p53 and 
TAp73 and stabilizes them by inhibiting the degradation 
by 20S proteasome (18) that is reversed by dicoumarol. 
TAp73 is also stabilized in cancer cells by a specific 20S 
proteasome inhibitor, withaferin A and the effect is due to 
the enhanced binding of TAp73 to NQO1 that only occurs 
upon the oxidative insult (19). Of note, it was demonstrated 
that R175H, R248H, and R273H mtp53s are resistant to 
dicoumarol-induced 20S degradation (20) and that the 
resistance is mediated by the enhanced binding of mtp53 to 
NQO1. This mechanism could at least partially contribute 
to the stabilization of mtp53 in cancer cells. 
Hence, as also commented by Oren and Kotler (11), 
the story on how mtp53 co-opts with Nrf2 to talk to 
proteasome is likely to continue to complete the picture. 
To this end, there seems to be a feedback loop between 
the transcriptional upregulation of Nrf2 by mtp53 and 
Nrf2-NQO1-mediated stabilization of unfolded mtp53 
protein. Yet, since different group of genes were found 
downregulated in TNBC upon different mtp53 silencing, 
it appears unlikely that the transcription-mediated 
regulation of proteasome machinery would be the only 
common mechanism underlying the GOFs phenotype. 
Studies divulging the interplay between ROS-scavenging 
enzymes and mtp53 GOFs phenotypes should advance 
understanding of GOFs phenotypes for better stratification 
of mtp53-harbouring patients to treatment.
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